Trusted Resource for Clinical Trials, Protocols & Progress
PK and PD Sampling Strategies in Phase 1: What to Measure and When PK and PD Sampling Strategies in Phase 1: What to Measure and When Introduction One of the most important goals of Phase 1 clinical trials is to understand how a new drug behaves in the human body. This is achieved by studying…
Read More “PK and PD Sampling Strategies in Phase 1: What to Measure and When” »
Risk-Based Monitoring in Phase 3 Clinical Trials: Methods, Tools, and Best Practices How to Implement Risk-Based Monitoring Strategies in Phase 3 Trials What Is Risk-Based Monitoring (RBM)? Risk-Based Monitoring (RBM) is a modern approach to clinical trial oversight that focuses on identifying, assessing, and mitigating the risks that could impact data quality, subject safety, and…
Read More “Risk-Based Monitoring in Phase 3 Clinical Trials: Methods, Tools, and Best Practices” »
Role of DSMBs and Ethics Committees in Phase 2 Trials Understanding the Role of DSMBs and Ethics Committees in Phase 2 Clinical Trials Introduction As investigational drugs progress into Phase 2 clinical trials, they are tested in larger patient populations and often for longer periods. This increases both the complexity and the ethical responsibilities of…
Read More “Role of DSMBs and Ethics Committees in Phase 2 Trials” »
Use of Patient Registries in Phase 4 Research: Design, Implementation, and Insights Leveraging Patient Registries in Phase 4 Trials for Long-Term Safety and Real-World Effectiveness What Are Patient Registries in Clinical Research? Patient registries are organized systems that collect uniform data on patients who share a particular condition, exposure, or treatment. In Phase 4 clinical…
Read More “Use of Patient Registries in Phase 4 Research: Design, Implementation, and Insights” »
Stopping Rules and Dose Limiting Toxicity (DLT) Criteria in Phase 1 Trials Stopping Rules and Dose Limiting Toxicity (DLT) Criteria in Phase 1 Trials Introduction Phase 1 clinical trials aim to evaluate the safety, tolerability, and pharmacokinetics of investigational products, especially in first-in-human (FIH) settings. One of the most critical aspects of early-phase trial design…
Read More “Stopping Rules and Dose Limiting Toxicity (DLT) Criteria in Phase 1 Trials” »
Data Collection Tools and eCRFs in Phase 3 Clinical Trials: Best Practices and Regulatory Insights How to Use eCRFs and Digital Tools for Efficient Data Collection in Phase 3 Trials Why Data Collection Matters in Phase 3 Clinical Trials Phase 3 clinical trials generate enormous volumes of clinical data from thousands of participants, across dozens…
Safety Monitoring Requirements in Phase 2 Trials Safety Monitoring in Phase 2 Trials: Procedures, Responsibilities, and Best Practices Introduction Phase 2 clinical trials mark the transition from safety-focused Phase 1 studies to trials evaluating both efficacy and continued safety in patients. As drugs are tested in larger populations and for longer durations, robust safety monitoring…
Read More “Safety Monitoring Requirements in Phase 2 Trials” »
Long-Term Safety Monitoring Protocols in Phase 4 Clinical Trials How to Design and Implement Long-Term Safety Monitoring in Phase 4 Studies Why Long-Term Safety Monitoring Is Essential After Drug Approval Once a drug is approved and released into the market, its journey is far from over. While clinical trials up to Phase 3 offer controlled…
Read More “Long-Term Safety Monitoring Protocols in Phase 4 Clinical Trials” »
Regulatory Requirements for Phase 3 Trials: A Comparative Overview of FDA, EMA, and CDSCO Guidelines Understanding Regulatory Guidelines for Phase 3 Trials Across FDA, EMA, and CDSCO Why Regulatory Requirements Matter in Phase 3 Trials Phase 3 clinical trials are the final and most comprehensive step before a drug or therapy is submitted for market…
Adverse Event Monitoring in Phase 1: Definitions, Reporting, and Grading Adverse Event Monitoring in Phase 1: Definitions, Reporting, and Grading Introduction Adverse event (AE) monitoring is at the heart of Phase 1 clinical trials, where the primary objective is to establish the safety and tolerability of a new investigational product (IP). Because participants are often…
Read More “Adverse Event Monitoring in Phase 1: Definitions, Reporting, and Grading” »
